Wedbush Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target hoisted by equities research analysts at Wedbush from $48.00 to $50.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush’s target price would indicate a potential upside of 26.39% from the stock’s current price.

KNSA has been the subject of a number of other reports. Citigroup lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. The Goldman Sachs Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. TD Cowen initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a “buy” rating and a $60.00 target price on the stock. Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. Finally, Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.33.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $39.56 on Tuesday. The company has a market capitalization of $3.00 billion, a P/E ratio of 87.91 and a beta of 0.04. Kiniksa Pharmaceuticals International has a one year low of $18.12 and a one year high of $44.42. The business’s 50 day simple moving average is $41.34 and its 200-day simple moving average is $36.60.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). The business had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company’s revenue for the quarter was up 61.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.18) EPS. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sanj K. Patel sold 121,248 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $38.90, for a total transaction of $4,716,547.20. Following the completion of the transaction, the chief executive officer directly owned 111,794 shares in the company, valued at approximately $4,348,786.60. The trade was a 52.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John F. Paolini sold 82,542 shares of the stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $37.14, for a total value of $3,065,609.88. Following the sale, the insider directly owned 61,324 shares of the company’s stock, valued at approximately $2,277,573.36. The trade was a 57.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 510,689 shares of company stock worth $20,009,290 over the last three months. Insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC increased its holdings in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares in the last quarter. Mariner LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 5.8% during the third quarter. Mariner LLC now owns 13,253 shares of the company’s stock worth $515,000 after buying an additional 732 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 4.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock worth $701,000 after buying an additional 771 shares in the last quarter. USA Financial Formulas bought a new position in shares of Kiniksa Pharmaceuticals International during the third quarter worth about $32,000. Finally, Nordea Investment Management AB raised its position in Kiniksa Pharmaceuticals International by 0.7% in the 3rd quarter. Nordea Investment Management AB now owns 131,074 shares of the company’s stock valued at $5,016,000 after buying an additional 914 shares during the last quarter. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.